Gerard Sanacora MD
Psychopharmacology
Professor of Psychiatry; Director, Yale Depression Research Program
Join to view full profile
34 Park StCnru At CmhcNew Haven, CT 06519
Phone+1 203-974-7560
Dr. Sanacora is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Gerard Sanacora, MD, is a translational neuroscientist and psychiatry expert based in New Haven, CT, specializing in psychopharmacology and interventional psychiatry. He completed his residency in psychiatry at Yale-New Haven Medical Center following his medical education and Ph.D. in Physiology and Biophysics at Stony Brook University Health Sciences Center School of Medicine. Since 1994, he has been a professor at Yale New Haven Hospital with expertise in experimental therapeutics and clinical trial methodologies treating mood and neurodegenerative disorders. Dr. Sanacora has contributed to several publications on depression and related treatments, and has also been involved in clinical trials, notably concerning the use of ketamine for treating depression in Parkinson's disease.
Education & Training
Yale-New Haven Medical CenterResidency, Psychiatry, 1994 - 1998
Stony Brook University Health Sciences Center School of MedicineClass of 1994
Certifications & Licensure
CT State Medical License 1996 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Ketamine for the Treatment of Depression in Parkinson's Disease Start of enrollment: 2021 Nov 23
Roles: Contact
Publications & Presentations
PubMed
- Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.Balwinder Singh, Hossam M Ali, Alessandro Miola, Nicolas A Nunez, Manoela V Fogaça
Neuropsychopharmacology. 2026-09-21 - NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results fro...Elan A Cohen, Gerard Sanacora, Koichiro Watanabe, Alla Feldbarg, Rainer-Georg Goeldner
Neuropsychopharmacology. 2026-09-05 - The Randomization Effect in a Double-Blind Placebo-Controlled Depression Study.Steven D Targum, Paulette Ceesay, Christopher Lines, Michael E Thase, Gerard Sanacora
Journal of Clinical Psychopharmacology. 2026-09-02
Press Mentions
Why Depression Can Resist TreatmentAugust 20th, 2026- For Many Americans, Depression Is Familiar. Here’s What We KnowJune 30th, 2026
- She Hoped Ketamine Would Rewire Her Brain. She Didn’t Live to See It WorkMarch 17th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: